From: Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy
Author - Year | Expansion | Purity | Functionality changes | ||
---|---|---|---|---|---|
Fold | Days | Media feed [L] | |||
T cell | |||||
 Lamers [125] - 1999 | 41–149 | 15 | NR | Predominantly CD3+ and CD8+ | Reduction in cytolytic activity at the end of the culture |
 Liu [126] - 1999 | 2 × 105–108 | 50–70 | NR | 95–99% CD4 + CD3+ T cells with virtual elimination of CD8+ cells | 50–95% of the cells had elevated expression of HLA-DR.; (IL2R)-a chain expression was increased; 40 to 90% of CD25 levels higher than freshly isolated CD4+ T cells |
 Nankervis [111] - 2018 | 117,450 (1st generation) | 13 | 2.2–2.4 | 90.9–98.8% CD3+ | NR |
439–557 (2nd generation) | 10 | 10.4–13.9 | 98.8–99.5% CD3+ | NR | |
 Coeshott [112] - 2019 | 543–1079 (high seeding) | 8 | 19.9 | 91.9–94.5% CD3+; CD4+ expanded preferentially | T-cell products had had low frequencies of cells bearing exhaustion markers |
951–1787 (low seeding) | 9 | 13.6 | 94.2–97.5% CD3+; CD8+ expanded preferentially | ||
TIL | |||||
17.3 | 22.3 | 40 | 96% T cells based on CD2+ reactivity. | Cells produced cytokines normally | |
PBL | |||||
 Pan [120] - 1999 | 104–187 | 11–12 | NR | NR | 57% transduction frequency |
 Shankar [121] - 1997 | ~ 100 | 10 | 5.5 | NR | 1–10% transduction frequency |
 Stroncek [122] - 1999 | ~ 200 | 17 | NR | NR | < 2.5% transduction frequency |